Wells Fargo & Company MN Purchases 7,037 Shares of Viking Therapeutics Inc (VKTX)

Wells Fargo & Company MN boosted its position in Viking Therapeutics Inc (NASDAQ:VKTX) by 12.0% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 65,810 shares of the biotechnology company’s stock after buying an additional 7,037 shares during the quarter. Wells Fargo & Company MN’s holdings in Viking Therapeutics were worth $1,146,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently made changes to their positions in VKTX. BlackRock Inc. raised its position in Viking Therapeutics by 681.0% in the 2nd quarter. BlackRock Inc. now owns 2,938,645 shares of the biotechnology company’s stock valued at $27,888,000 after buying an additional 2,562,356 shares during the last quarter. Janus Henderson Group PLC bought a new position in Viking Therapeutics in the second quarter valued at approximately $19,552,000. Northern Trust Corp grew its stake in Viking Therapeutics by 524.2% in the second quarter. Northern Trust Corp now owns 492,845 shares of the biotechnology company’s stock valued at $4,678,000 after purchasing an additional 413,892 shares in the last quarter. Columbus Circle Investors bought a new position in Viking Therapeutics in the third quarter valued at approximately $5,962,000. Finally, Macquarie Group Ltd. bought a new position in Viking Therapeutics in the second quarter valued at approximately $3,133,000. 59.80% of the stock is currently owned by institutional investors and hedge funds.

Shares of NASDAQ VKTX opened at $8.32 on Friday. Viking Therapeutics Inc has a 12 month low of $3.69 and a 12 month high of $24.00. The company has a market cap of $600.98 million, a PE ratio of -10.53 and a beta of 3.01.

Viking Therapeutics (NASDAQ:VKTX) last issued its earnings results on Friday, November 9th. The biotechnology company reported ($0.11) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.12) by $0.01. On average, research analysts anticipate that Viking Therapeutics Inc will post -0.43 earnings per share for the current fiscal year.

A number of research analysts have weighed in on the company. B. Riley assumed coverage on Viking Therapeutics in a research note on Tuesday, December 11th. They issued a “buy” rating and a $16.00 price target for the company. Roth Capital raised their price target on Viking Therapeutics from $13.00 to $24.00 and gave the company a “buy” rating in a research note on Wednesday, September 19th. Raymond James upgraded Viking Therapeutics from an “outperform” rating to a “strong-buy” rating and set a $43.00 price target for the company in a research note on Monday, November 19th. They noted that the move was a valuation call. SunTrust Banks raised their price target on Viking Therapeutics to $28.00 and gave the company a “buy” rating in a research note on Wednesday, September 19th. Finally, Maxim Group restated a “buy” rating and issued a $28.00 price target on shares of Viking Therapeutics in a research note on Thursday, November 8th. One equities research analyst has rated the stock with a sell rating, seven have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Viking Therapeutics presently has an average rating of “Buy” and a consensus price target of $26.29.

WARNING: “Wells Fargo & Company MN Purchases 7,037 Shares of Viking Therapeutics Inc (VKTX)” was originally reported by Stock Observer and is the sole property of of Stock Observer. If you are reading this article on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark law. The correct version of this article can be read at https://www.thestockobserver.com/2019/01/12/wells-fargo-company-mn-purchases-7037-shares-of-viking-therapeutics-inc-vktx.html.

About Viking Therapeutics

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures.

Featured Article: NASDAQ Stock Market Explained

Want to see what other hedge funds are holding VKTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Viking Therapeutics Inc (NASDAQ:VKTX).

Institutional Ownership by Quarter for Viking Therapeutics (NASDAQ:VKTX)

Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply